November 9, 2023

Life Sciences BC seeks to raise the profile of our members and supporters, highlight their achievements, and promote BC's dynamic life sciences ecosystem. If you have news or a story to share, let us know. You can find previous editions of BioLinks newsletters and other resources on our website at News/Publications.

We were delighted to see strong representation from key organizations such as Trade & Invest British Columbia and Global Affairs Canada. Attendees also heard insightful remarks from The Honourable Brenda Bailey and Fazil Mihlar, the Minister and Deputy Minister of BC's Ministry of JEDI.

The 25 company pitches were of the highest calibre, and the atmosphere in the room throughout the day and during the networking reception was electric!

You can learn more about the exciting pitching company innovations here.

Thank you to our generous sponsors and supporters for making this incredible event possible.

The Okanagan life sciences sector's energy, passion, and innovation shone brightly at this week’s Showcase Series: Kelowna event! Bringing the regional community together was a tremendous experience.

We extend our sincere gratitude to our speakers who shared invaluable insights, including Phil Barker and Dr. Thuy Dang of the University of British Columbia – Okanagan, one of our event sponsors, as well as Dr. Francois Louw of UBC’s Department of Family Practice, Chris Bunka of Lexaria Bioscience, Carollynn Schafer of Accelerate Okanagan, Dr. Deanne Taylor from Interior Health, and Roger Francis of Michael Smith Health Research BC, also an event sponsor. Thanks to all the participants for making this another excellent showcase event!

While in Kelowna, we took the opportunity to present to an enthusiastic audience of students at the University of British Columbia - Okanagan (UBCO) on the many employment opportunities in BC's growing life sciences sector. Students also enjoyed engaging presentations from LifeLabs Medical Laboratory Services, Lexaria Bioscience, and the Interior Health Authority, which provided valuable real-world insights.

While at UBCO, we visited the School of Engineering and learned more about the Faculty of Science's ambitious plans for a Master of Biotechnology program, aiming to bridge the gap between academic institutions and the biotechnology industry.

Kelowna's remarkable talent, energy, and enthusiasm underpin the growing strength of the Okanagan life sciences sector!

We're thrilled to announce that we are one of the delivery partners for the new AccelerateIP (AIP) program, a groundbreaking initiative led by New Ventures BC in partnership with Innovate BC, which provides startups with valuable education and support to safeguard, manage, and maximize the potential of their intellectual property.

By participating in AIP, companies may qualify for up to $85,000 in financial support to assist with the legal expenses related to IP strategy and implementation! You can learn more about this program and how LSBC can help here.

Registration is now open for our annual Life Sciences BC Holiday Party! Get ready to unwind, mingle with colleagues, and celebrate another successful year in the life sciences! This year’s event will be held at the Vancouver Marriott Pinnacle Downtown Hotel on Thursday, December 14th, from 5:00 to 7:00 PM PT. Learn more. 

If you are on Vancouver Island, you won't want to miss our first-ever Vancouver Island Winter Social hosted by Starfish Medical on Nov. 22. Register here!

Registration is also open for our Blakes Breakfast Speaking Series: Preparing for J.P. Morgan Week, which is designed to provide valuable tips and advice to attendees, assisting them in navigating the myriad activities scheduled throughout the week.

Join us to enhance your experience and make the most of the conference! You can learn more and register here.

Member Highlights 

AdMare BioInnovations' Vice President of Research, Dr. Joseph Mancini, was recently profiled in PharmaFEATURES, sharing insights into his career path and discussing adMare's innovative approach to transforming the Canadian Life Sciences landscape. Read the article here. 

Recent findings from the University of British Columbia and the Djavad Mowafaghian Centre for Brain Health, published in Cell Reports (Cell Press), offer valuable insights into the factors behind brain cell death after stroke and traumatic brain injury and potential strategies for their preservation. Learn more. 

New Member

Evolved Therapeutics is focused on establishing innovative antibody discovery platforms to enable the discovery of first- and best-in-class therapeutics.

Lexaria Bioscience Corp.'s patented drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients enter the bloodstream through oral delivery. 

Piech Communications is a boutique agency that delivers results-focused PR and content for organizations, start-ups and researchers advancing the latest science. 

Moderna Canada is a pharmaceutical and biotechnology company that focuses on RNA therapeutics, primarily mRNA vaccines. 

Welcome all to the LSBC community!

Industry Highlights

This week is Women and Girls in STEAM week in BC. Science World recently shared a video featuring The Honourable Brenda Bailey of BC’s Ministry of JEDI, who shared her STEAM journey and passion for science and technology. Watch it here.

The Greater Vancouver Board of Trade will welcome The Honourable Minister François-Philippe Champagne, Canada’s Minister of Innovation, Science & Industry, on Nov. 14 to discuss Canada's innovation landscape, focusing on clean technology, quantum, life sciences, and AI and how the federal government is driving innovation and economic growth. Learn more about this upcoming event here.

The Kelowna General Hospital Foundation recently received a generous $5 million donation from the Jim Pattison Foundation, its largest gift to a hospital in B.C.’s Interior and the first that targets innovation. This donation will help establish a new Centre for Health System Learning & Innovation in collaboration with Interior Health and the Kelowna General Hospital Foundation. The center will primarily concentrate on health system transformation. Learn more.

The BC government will host an exhibit at Medica in Germany from 13-16 November. The world’s largest trade show for the medical device sector, Medica attracts European, Asian and North American device manufacturers, buyers and distributors, including hospital procurement officers. Over 100,000 attendees gather annually in Dusseldorf to network and showcase technologies and devices for export or investment. This year, the show welcomes the participation of 10 BC companies, including LSBC members Response Biomedical and Rostrum Medical. For further information, contact Laetitia MacDougall.

Canada is investing more than $4.7 million in the Health System Impact Fellowship program, which supports researchers' career development through partnerships with healthcare organizations. This initiative will assist 11 Ph.D. students and 27 postdoctoral fellows embedded in 31 health organizations across 14 Canadian universities, addressing complex, high-priority challenges and strengthening the country's healthcare systems. Learn more.

Canada is establishing the Dementia Research and Innovation Funders Alliance, led by the CIHR Institute of Aging, to unify dementia research funding organizations. This initiative aims to advance dementia research, promote training, assess the research landscape, identify gaps, and mobilize knowledge from Canadian-funded dementia research. Learn more.

Canada's Minister of Innovation, Science, and Industry participated in the first-ever British AI Safety Summit, where he emphasized Canada's Voluntary Code of Conduct on Advanced Generative AI Systems. Leaders from 28 countries and the EU signed The Bletchley Declaration, committing to address AI risks, promote global understanding, and collaborate on safety-testing AI models. Learn more.

Kudos

Congratulations to Brenda Irwin, the CDL-Vancouver's Associate Mentor of the Year Award recipient! Brenda is also a dedicated "Entrepreneur in Residence" within our Investor Readiness Program, where she provides invaluable mentorship to SMEs in the program. Learn more.

Kudos to Genome BC for their podcast Nice Genes Seasons 1 and 2, which will now be featured on Air Canada's in-suite entertainment services! Learn more.

Congratulations to Canary Medical, named the Gold Winner of the Merit Awards for healthcare, recognizing services, products, innovations and technologies shaping the healthcare marketplace. See the full list of award winners here and learn more here.

Kudos to St. Paul’s Foundation President & CEO Dick Follet for being honoured with the prestigious Lifetime Achievement Award by the AFP Greater Vancouver Chapter. This recognition celebrates his outstanding leadership and unwavering commitment to community service. Learn more.

Business in Vancouver has announced its 2023 Forty under 40 Award recipients, which includes Hussein Alibhai of STEMCELL Technologies – congratulations! See the complete list of winners here.

People on the Move

Former British Columbia premier John Horgan has been appointed Canada’s next ambassador to Germany. Learn more.

Dr. Ghania Chikh has joined Acuitas Therapeutics as Senior Director, Vaccine Development, bringing decades of drug development experience, specializing in vaccine development and immunotherapeutics. Learn more.

Toufic Boubez, a seasoned entrepreneur and technology leader, has joined Pender Ventures as a Venture Partner. Learn more.

Applications Open

Applications for the winter 2023 Cohort of entrepreneurship@UBC’s Venture Founder program supporting UBC-affiliated entrepreneurs are now open! Applications are due Dec.1. Learn more.

Canadian Institutes of Health Research is seeking new members to join its HIV/AIDS and STBBI Research Advisory Committee. It is specifically looking for experts and researchers in the areas of virology, immunology, or microbiology, and primary care physicians for people with lived and living experience of long-lasting sexually transmitted and blood-borne infections, such as HIV/AIDS and Hepatitis C. Applications are due Dec. 31. Learn more. 

We invite you to explore our expanded list of current life sciences application opportunities by clicking the button below.

Upcoming LSBC events at-a-glance

Nov. 29/30 - LSBC, in partnership with Biotech Primer, is pleased to present BioBasics 101: The Biology of Biotech for the Non-Scientist.



Dec. 13 - Attending J.P. Morgan Conference Week and need navigation tips? We invite you to join us for our Blakes Breakfast Speaking Series: Preparing for J.P. Morgan Week

Dec. 14 - Join us alongside your industry colleagues for an evening of relaxed camaraderie as we toast the holiday season at the annual Life Sciences BC Holiday Party.

Until next week,

Wendy and the LSBC team

WELL Health Launches “WELL Longevity+” A Program Designed to Provide the Most Advanced Preventative Care Available

WELL Longevity+ is a progressive extension of its preventative health division and designed to redefine the future of personal and corporate wellness. WELL Longevity+ is at the forefront of Longevity Medicine, utilizing state-of-the-art technologies and precision diagnostic testing to proactively identify potential conditions such as cancer, heart disease, and neurodegenerative diseases... READ MORE

Xomotion Created by SFU Researchers to Be World’s Most Advanced Exoskeleton for Mobility Challenged

The state-of-the-art robotic exoskeleton known as XoMotion is the result of a decade of research and the product of an SFU spin off company, Human in Motion Robotics (HMR) Inc. The company has recently garnered millions in investment, an overseas partnership and a suite of new offices in Vancouver... READ MORE

Xenon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, reported financial results for the third quarter ended September 30, 2023 and provided a corporate update... READ MORE

Aurinia Presents Breadth of Data From Aurora Clinical Program Underscoring Value of Lupkynis (Voclosporin) For Patients With Lupus Nephritis at Acr 2023

A propensity analysis of AURORA 1 suggested that initial therapy with LUPKYNIS® plus standard of care improved safety and demonstrated earlier reductions in proteinuria when compared to a conventional regimen consisting of higher doses of both mycophenolate mofetil and glucocorticoids alone...

READ MORE

Type 2 Diabetes and Prediabetes Can Be Reversed With Personalized Lifestyle Education and Support From Lifestylerx and Lifelabs

LifestyleRx is a virtual physician-led program that aids patients in adopting key lifestyle changes to achieve sustainable remission of prediabetes or Type 2 diabetes. It offers personalized education and virtual care to support lifestyle changes, focusing on key areas such as diet, sleep, light exercise, stress reduction, and more. The program is available at no cost to patients with OHIP and MSP coverage... READ MORE

PharmAla Completes Historic First Shipment of MDMA and Psilocybin to Cortexa

PharmAla Biotech Holdings Inc., a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including MDMA), is pleased to announce that it has completed its first shipment of MDMA and psilocybin to Cortexa, its 50:50 Australian Joint Venture with Vitura Health Limited (ASX: VIT). This shipment marks the first time that any molecules recently re-scheduled under the Authorized Prescriber Scheme were brought into Australia explicitly for use under that scheme, rather than for clinical trial purposes... READ MORE

Renaissance BioScience Corp. Secures Additional Patents for Acrylamide-Reducing Yeast Technology

Renaissance BioScience Corp., a leader in bioengineering for the global food industry, is pleased to announce that it has recently been granted patents for its non-GMO acrylamide-reducing yeast from regulatory authorities in Denmark, France, Great Britain, Italy, Sweden, Mexico, Ukraine, and South Africa. These patents join its portfolio of patents in ten other key markets, further strengthening the company’s intellectual property position... READ MORE

WELL Health Announces Record Patient Visits and Total Care Interactions for Q3-2023 Resulting in Record Quarterly Revenue

WELL Health Technologies Corp. (TSX: WELL, OTCQX: WHTCF) (“WELL”), a digital healthcare company focused on positively impacting health outcomes by leveraging technology to empower healthcare practitioners and their patients globally, is pleased to announce it has achieved another record in patient visits and this achievement has driven record revenues for Q3-2023... READ MORE

Zymeworks Provides Corporate Update And Reports Third Quarter 2023 Financial Results

Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel multifunctional biotherapeutics, reported financial results for the three and nine months ended September 30, 2023 and provided a summary of recent business highlights... READ MORE

Dr. Ghania Chikh Named Senior Director, Vaccine Development at Acuitas Therapeutics

Dr. Ghania Chikh has joined Acuitas Therapeutics, Inc. as Senior Director, Vaccine Development, Chief Scientific Officer Dr. Ying Tam recently announced. In this senior leadership role, Dr. Chikh will oversee the vaccine development program, working with Acuitas’ global partners. She will also lead internal programs focused on identifying, developing and optimizing the proprietary Acuitas lipid nanoparticle (LNP) delivery technology to support next-generation mRNA LNP vaccines... READ MORE

Clairvoyant Therapeutics to join Empowered Startups Incubation Program in Portugal

European Parliament was the setting for the ground-breaking announcement, which was part of an enlightening presentation from Clairvoyant CEO and Co-Founder, Damian Kettlewell. Kettlewell provided industry perspective during an event focused on exploring regulatory pathways for psychedelic therapies in Europe... READ MORE

Crohn’s and Colitis Canada and Pfizer Canada Announce 2023 Women in IBD Award Recipients

Crohn’s and Colitis Canada and Pfizer Canada are pleased to announce the two recipients of the 2023 Women in Inflammatory Bowel Disease (IBD) Awards. The winners were selected based on the nominee’s impact on the Canadian IBD community, contributions to the mission of Crohn’s and Colitis Canada, and demonstration of innovation and leadership in the field of IBD... READ MORE

Canadian Blood Services Includes HyQvia® on its Formulary

Takeda Canada Inc. (“Takeda”) is pleased to announce that Canadian Blood Services (CBS) has included HyQvia® (Normal Immunoglobulin [Human]) 10% & Recombinant Human Hyaluronidase solution for subcutaneous infusion) as replacement therapy for primary humoral immunodeficiency (PI) and secondary humoral immunodeficiency (SI) in adult patients on its formulary... READ MORE

Seagen Highlights First Solid Tumor Data for an ADCETRIS® (brentuximab vedotin) Immunotherapy Combination and Preclinical Data for Novel CD30-Directed Antibody-Drug Conjugate at Society for Immunotherapy of Cancer (SITC) Annual Meeting

Seagen Inc. (NASDAQ: SGEN) announced the first presentation of data evaluating ADCETRIS® (brentuximab vedotin) in combination with an anti-PD-1 checkpoint inhibitor in non-small cell lung cancer (NSCLC) and melanoma, and shared preclinical data for an investigational CD30-directed antibody-drug conjugate (ADC) that uses a novel tripeptide linker. The studies were presented at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, taking place November 3-5, 2023, in San Diego... READ MORE

InMed Announces Presentation of INM-755 Phase 2 Clinical Study Results at 12th World Congress on Itch (WCI) 2023

InMed Pharmaceuticals Inc., a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, announced that an abstract describing the Phase 2 clinical study of investigational drug INM-755 cannabinol (“CBN”) cream for the treatment of symptoms in patients with epidermolysis bullosa (“EB”), a rare genetic skin disease, has been accepted as an oral presentation at the 12th World Congress on Itch... READ MORE

Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology

Under the terms of the agreement, Prelude and AbCellera will jointly discover, develop, and commercialize products emerging from the collaboration. AbCellera will lead manufacturing activities and Prelude will lead clinical development and global commercialization, subject to AbCellera’s option to co-promote any resulting commercial products in the United States... READ MORE

Novartis’ $3.2B Chinook Buy Pays Off with Promising Phase III IgAN Data

Topline data from the Phase III ALIGN study showed that Novartis’ investigational endothelin A receptor antagonist atrasentan met its primary endpoint, significantly reducing protein in the urine of patients with IgA nephropathy, the company announced. Novartis did not reveal specific data in its announcement but said that patients treated with atrasentan saw a “clinically meaningful and highly statistically significant” decrease in proteinuria compared with placebo... READ MORE

Research Study on Road to Recovery Initiative Will Evaluate Program’s Impact, How Best to Improve Care

The Road to Recovery Initiative (R2R) is an innovative model of care that aims to transform the way substance use treatment is coordinated and delivered in BC. Co-developed by the Providence Health Care (PHC) Division of Addiction and the BC Centre on Substance (BCCSU), it will focus on providing a full continuum of substance use care, to help patients access the right support when they need it... READ MORE

At TRIUMF Innovations, we focus on the business of science. We are the commercialization arm of TRIUMF, Canada’s particle accelerator centre, dedicated to linking cutting-edge science and technology to tangible business opportunities.

TRIUMF Innovations acts as a connector to the business world by providing market opportunities for applied physics-based technologies that emerge from the TRIUMF network – by streamlining access to TRIUMF’s world-class expertise and infrastructure, and by connecting TRIUMF researchers and technologies to the world via industry partnerships, licensing, and business development. LEARN MORE

Government of Canada Invests More Than $4.7m in Health Researchers Who Will Tackle High-Priority Challenges in Our Health Systems

The Government of Canada continues to invest in our country’s brightest minds to enable the next generation of health researchers to apply their talents, working directly with health organizations, to tackle real-world health system challenges. The Honorable Mark Holland, Minister of Health, announced an investment of more than $4.7M in the Health System Impact Fellowship program... READ MORE

Canada Helps Shape Global Dialogue on the Responsible and Safe Use of Artificial Intelligence

The Honourable François-Philippe Champagne, Minister of Innovation, Science and Industry, concluded a two-day visit to Bletchley Park, United Kingdom, where the British government hosted the first-ever AI Safety Summit. During the summit, leaders discussed how best to manage the risks from so-called frontier AI systems—highly capable general-purpose AI software programs or algorithms that match or exceed present-day capabilities... READ MORE

New Alliance to Advance Dementia Research in Canada

As part of the first-ever National Strategy for Drugs for Rare Diseases announced in March 2023, the Government of Canada committed to establishing a national governance structure to support the implementation of the National Strategy and to help improve consistent access and affordability of effective drugs for rare diseases across the country... READ MORE

Quality Control Supervisor – Deeley Research Centre, Victoria

The Quality Control Supervisor will support the manufacturing, quality control and quality assurance activities for the BCCA’s Cancer Immunotherapy Program, at the BCCA's Deeley Research Centre (DRC). The Quality Control Supervisor will provide supervision of the Quality Control group, ensuring efficient, orderly and seamless operation of the quality control laboratory at the CFIL including resource scheduling...LEARN MORE

Research Associate II, Protein Engineering

The role involves active participation in protein purification for multispecific antibodies to support research. Responsibilities include characterizing protein therapeutics, designing and executing experiments for screening antibody-based therapeutics, troubleshooting methods, and analyzing data. The candidate must maintain an organized lab, adhere to scientific standards and OH&S regulations, and actively foster collaborative relationships within the organization...LEARN MORE

Research Associate II – Protein Sciences

As a Research Associate II in Protein Sciences within the Integrated Sciences group, your key responsibilities include supporting protein activities, assisting the antibody generation team, documenting results, collaborating across teams, and managing program timelines to advance therapeutic efforts. Join our motivated drug discovery team, dedicated to delivering transformative medicines to patients while fostering an innovative and collaborative environment...LEARN MORE

Research Associate II – Antibody Generation

As a Research Associate II in the Antibody Generation group, you'll be responsible for optimizing antibody generation platforms, identifying lead antibody candidates, collaborating across teams, documenting results, presenting data, supporting innovative research strategies, and fostering a culture of innovation and collaboration. Join our dedicated drug discovery team with a focus on delivering transformative medicines to patients...LEARN MORE

Associate Scientist – Molecular Biology, Integrated Sciences

As an Associate Scientist in the Integrated Sciences group, your key responsibilities involve developing innovative assay solutions, providing support to the antibody generation team, improving core platforms, documenting results, collaborating across functions, managing program timelines, and fostering innovation. We seek candidates passionate about innovation and technical challenges to join our motivated drug discovery team dedicated to delivering transformative medicines while maintaining a culture of respect and trust...LEARN MORE

Senior Scientist, Formulation

NanoVation Therapeutics (NTx) is looking for an innovative and collaborative Senior Scientist, Formulation to join our team. Reporting to the CSO, the Senior Scientist, Formulation will work closely with the Formulation Team and will be responsible for designing and executing protocols related to internal and client-based projects, and subsequent data analysis. Our ideal candidate thrives on contributing collaboratively in a fast-paced, innovative environment and is open and interested in learning a variety of different research techniques...LEARN MORE

Scientist, Preclinical Development

This is a full-time Scientist role on the Preclinical Development team at Integrated Nanotherapeutics Inc. involving work across multiple sites: headquarters in Burnaby, BC, with in vivo research activities and flow cytometry conducted at sites in Vancouver, BC and flexibility for some remote work. The successful candidate will contribute to our R&D programs in antigen-specific immune tolerance by applying in vivo mouse and cellular immunology skills to develop and advance lead lipid nanoparticle-based products through preclinical pipelines...LEARN MORE

Biomanufacturing Trainer and Site Manager

Reporting to the Associate Director of Technical Training they will take a leadership role in overseeing the set-up and operations of the greater Vancouver Training Facility and supporting the company’s overall strategy. As an expert in the field of biopharmaceutical manufacturing and bioprocessing, the Biomanufacturing Trainer/Site Lead will work with the Associate Director of Technical Training and other company team members to deliver world-class in-person, virtual and practical hands-on training to a variety of learners...LEARN MORE

Associate I

The QC Associate is responsible for performing routine samples analysis in accordance with GMP and Evonik policies and practices. The QC Associate will also assist with equipment calibration/qualification and analytical method validation, as well as participating in quality system improvement initiatives. This is a lab-based position which will entail a high volume of testing in a regulated laboratory environment...LEARN MORE

Senior Manager, Site Engagement Lead

The role involves leading strategic partnerships with key clinical trial sites, ensuring collaboration and operational efficiency, and serving as a subject matter expert. The responsibilities include maintaining strong relationships with sites, sharing insights, resolving issues, and centralizing operational information to enhance clinical trial execution, while also collaborating with internal stakeholders and contributing to process improvements...LEARN MORE

Principal Scientist/Associate Director Biologics

Abdera Therapeutics is seeking a highly motivated and skilled leader in antibody discovery with a proven track record of antibody campaigns. This position will provide an exciting and dynamic opportunity to positively contribute to and lead research programs and teams developing next-generation targeted radiopharmaceutical therapies...LEARN MORE

Mitacs Post-Doc

A postdoctoral position is available in the laboratory of Prof. Filip Van Petegem at the University of British Columbia. The goal is to apply state of the art computational protein design methods to create novel protein molecules to enable structural cryo-EM characterization of therapeutic candidates and their target. The project is a collaboration with Amgen, one of the world’s leading biotechnology companies, and is supported through a MITACS scholarship...LEARN MORE

Scientist, Clinical Pharmacokinetics

This role represents Clinical Pharmacology in multi-functional teams supporting late-stage discovery programs. It involves analyzing clinical PK data, assisting in study design, maintaining knowledge of drug development approaches, and contributing to regulatory and scientific documentation. The position also requires building client relationships, summarizing and presenting results, and coordinating with SAS programmers and Clinical Operations for efficient deliverables...LEARN MORE

Associate Scientist, In Vivo Pharmacology

This role involves overseeing in vivo immuno-oncology experiments, managing internal and external studies, and providing hands-on support for mouse handling and administrative tasks. It also encompasses pharmacodynamic evaluations, technology exploration, mentorship, result presentation, and ensuring compliance with scientific standards and regulations while promoting collaboration...LEARN MORE

Research Associate I, Analytics

The role involves conducting experiments, providing research support, and performing antibody/antigen purification through chromatography techniques. Additionally, it includes supporting protein characterizations, maintaining scientific standards, and fostering collaborative working relationships within the organization while adhering to safety regulations and documentation procedures. The position also entails maintaining a safe and organized laboratory environment and ensuring the procurement and organization of reagents and chemicals for the Analytics team...LEARN MORE

At NovaSense Technology, we are revolutionizing healthcare with our cutting-edge soft, flexible and stretchable sensing technology designed to accurately measure pressure and shear over extended periods. Our innovation aims to prevent pressure injuries, enhancing lives through intelligent sensing and personalized user solutions. LEARN MORE

Salyx Medical is an incorporated technology company that bridges the gap between the senior population, health sector and their loved ones, by creating an accurate and easy to use device to track 5 vitals and a digital ecosystem that is accessible to the user's selected health care providers, family and friends. LEARN MORE

Tickit Health is pioneering digital mental health care with our innovative platform that utilizes a Digital Empathy framework. Designed to personalize youth mental health support, our multilingual, low-literacy digital tools bridge gaps in traditional care. Serving 85,000 patients across 750+ sites, we seamlessly integrate with major medical systems, positioning us at the forefront of the rapidly growing USD 69.44 billion market. More than a service, our unique digital platform focuses on accessible and culturally sensitive care, leading the shift towards pervasive, personalized mental health support.

LEARN MORE

Lexaria Bioscience Corp.'s patented drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with over 35 patents granted and many patents pending worldwide. LEARN MORE

Stay current by subscribing to this and our events newsletter!

Follow LSBC on Social Media!